Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2022-10-28
Target enrollment:
Participant gender:
Summary
ONAWA is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates the
effect of onapristone (ONA) on proliferation after 3 weeks of treatment in postmenopausal
women with ER+/PgR+ and HER2-negative early breast cancer amenable to pre-operative endocrine
therapy and surgery.